atezolizumab

Known as: anti-PDL1, immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer 
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
BACKGROUND The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor… (More)
Is this relevant?
Review
2017
Review
2017
The treatment of bladder cancer has evolved over time to encompass not only the traditional modalities of chemotherapy and… (More)
  • figure 1
  • table 1
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and… (More)
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab… (More)
  • table 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination… (More)
Is this relevant?
2007
2007
Acceptance of the fetus expressing allogeneic paternal Ags by the mother is a physiologic model of transplantation tolerance… (More)
Is this relevant?
1991
1991
  • M. C. Beniers, Bergerat, +14 authors A. Schalken
  • Springer Berlin Heidelberg
  • 1991
 
Is this relevant?